This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- Sam Mosley⇑
- Kate Moreau
- Department of Biomedical and Health Sciences, University of Vermont
- Department of Biomedical and Health Sciences, University of Vermont
- Address for Correspondence: Sam Mosley
, Department of Biomedical and Health Sciences, University of Vermont, smosley{at}uvm.edu
ABSTRACT
Amyloid light-chain (AL) amyloidosis is a rare plasma cell disorder characterized by the extracellular deposition of misfolded immunoglobulin light chains, resulting in organ dysfunction and high mortality. Delayed and missed diagnoses are common owing to nonspecific, heterogeneous symptoms. Evidence shows that racial and ethnic minorities, individuals with low socioeconomic status, and patients without access to specialized centers are more likely to experience delayed diagnoses and reduced treatment access. This introduces the potential for populations affected by AL amyloidosis to be excluded from clinical cohorts. From a laboratory perspective, diagnosis relies heavily on serum and urine free light-chain assays. Reference intervals present an ongoing challenge as recommendations shift from population-specific to population-inclusive models and as organ dysfunction confounds urine-based assays. Refinement of reference intervals using diverse cohorts, development of novel assays targeting amyloidogenic light chains, risk-based stratification approaches, and artificial intelligence–based predictive models show promise for earlier disease recognition. Addressing diagnostic delays while minimizing unnecessary interventions requires coordinated improvements in laboratory testing, provider education, infrastructure, and population-based research.
- AI - artificial intelligence
- AL - amyloid light chain
- ATTR-CM - transthyretin amyloid cardiomyopathy
- dFLC - difference between involved and uninvolved light chains
- eGFR - estimated glomerular filtration rate
- EHR - electronic health record
- FLC - free light chain
- MDT - multidisciplinary team
- MGUS - monoclonal gammopathy of undetermined significance
- SES - socioeconomic status
- VistA - Veterans Health Information Systems and Technology Architecture
- Accepted July 3, 2026.
American Society for Clinical Laboratory Science






